Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLAGOV study of AMG 145 in coronary atherosclerosis
NL-OMON41708Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Aug 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dyslipidemia, atherosclerosis, coronary arteriosclerosis and 1 more comparing AMG 145 + atorvastatin with Placebo + atorvastatin (2 arms). Primary endpoint: Change in percent atheroma volume. Started Aug 2013; status: active, not recruiting.
02
Drugs
evolocumab
03
Conditions
dyslipidemiaatherosclerosiscoronary arteriosclerosishypercholesterolemia
Beyond the preview
Go deeper on NL-OMON41708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41708.